G. Constantine

M. D. de Kam, A. Cohen, C. Kluft, 2011, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules)

G. Constantine, R. Lobo, F. Stanczyk, 2019, Menopause.

Assessment of ospemifene or lubricants on clinical signs of VVA.

G. Constantine, S. Kingsberg, W. Koltun, 2014, The journal of sexual medicine.

Compounded non-FDA–approved menopausal hormone therapy prescriptions have increased: results of a pharmacy survey

G. Constantine, J. Pinkerton, 2015, Menopause.

Bridging analysis of the efficacy and safety of bazedoxifene in Japanese and global populations of postmenopausal women with osteoporosis

A. Chines, T. Sugimoto, G. Constantine, 2013, Journal of Bone and Mineral Metabolism.

Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis

Jacques P. Brown, C. Christiansen, J. Adachi, 2010, BMC musculoskeletal disorders.

Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence

H. Taylor, G. Constantine, D. Archer, 2015, Menopause.

Endometrial Effects of Bazedoxifene Acetate, a Novel Selective Estrogen Receptor Modulator, in Postmenopausal Women

E. Baracat, G. Constantine, D. Archer, 2005, Obstetrics and gynecology.

Efficacy and safety of bazedoxifene in postmenopausal Asian women

K. Tsai, A. Chines, G. Constantine, 2008, Osteoporosis International.

Aortic Valvular Regurgitation: Prevalence and Clinical Characteristics in a Predominantly Obese Adult Population Not Taking Anorexigens

J. Gardin, G. Constantine, C. Reid, 2006, Echocardiography.

Systemic estradiol levels with low-dose vaginal estrogens

R. Santen, G. Constantine, S. Mirkin, 2019, Menopause.

The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy

H. Kushner, J. Simon, G. Constantine, 2017, Menopause.

Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.

G. Constantine, R. Lobo, J. Pickar, 2009, Fertility and sterility.

Estradiol vaginal inserts (4 µg and 10 µg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data

J. Simon, G. Constantine, D. Archer, 2018, Current medical research and opinion.

Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial

J. Simon, G. Constantine, R. Kagan, 2017, Menopause.

Pharmacokinetics and tolerability of a novel progesterone intravaginal ring in sheep

Bridget A. Martell, J. Vidal, G. Constantine, 2019, Drug Delivery and Translational Research.

Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial

G. Bachmann, G. Constantine, R. Feldman, 2011, Menopause.

Sustained efficacy of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: Results of a 5-year, randomized, placebo-controlled study

S. Silverman, J. Adachi, J. Zanchetta, 2010 .

Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis

A. Chines, G. Constantine, D. Archer, 2009, Menopause.

Evaluation of Bazedoxifene/Conjugated Estrogens for the Treatment of Menopausal Symptoms and Effects on Metabolic Parameters and Overall Safety Profile

G. Constantine, R. Lobo, J. Pickar, 2010 .

Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine.

J. Gardin, N. Weissman, J. Panza, 2001, JAMA.

Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial

G. Constantine, W. Utian, J. Pickar, 2009, Menopause.

TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women

J. Simon, G. Constantine, R. Kagan, 2019, Climacteric : the journal of the International Menopause Society.

A vaginal estradiol softgel capsule, TX-004HR, has negligible to very low systemic absorption of estradiol: Efficacy and pharmacokinetic data review.

J. Simon, G. Constantine, D. Archer, 2017, Maturitas.

Patient acceptability and satisfaction with a low-dose solubilized vaginal estradiol softgel capsule, TX-004HR

I. Goldstein, H. Kushner, G. Constantine, 2017, Menopause.

Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial

G. Constantine, J. Pinkerton, E. Hwang, 2013, Menopause.

articleSafety of bazedoxifene in a randomized , double-blind , placebo-and active-controlled phase 3 study of postmenopausal women with osteoporosis

Jacques P. Brown, C. Christiansen, J. Adachi, 2015 .

Early onset of action with a 17β-estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareunia.

G. Constantine, S. Mirkin, A. Kaunitz, 2019, Menopause.

Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptoms

M. McClung, G. Constantine, R. Kagan, 2020, Menopause.

Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial.

D. Apter, G. Constantine, G. Grubb, 2009, Contraception.

Original research article Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial ☆

D. Apter, G. Constantine, G. Grubb, 2009 .

Occurrence of menses or pregnancy after cessation of a continuous oral contraceptive.

N. Zhang, G. Constantine, G. Grubb, 2008, Fertility and sterility.

Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results.

G. Constantine, D. Archer, J. Jensen, 2006, Contraception.

Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review

K. Lapane, G. Constantine, S. Mirkin, 2019, Menopause.

Increased Incidence of Endometrial Cancer Following the Women's Health Initiative: An Assessment of Risk Factors

G. Constantine, S. Goldstein, S. Graham, 2019, Journal of women's health.

Endometrial safety of ospemifene: results of the phase 2/3 clinical development program

G. Constantine, D. Archer, S. Goldstein, 2015, Menopause.

Incidence of genitourinary conditions in women with a diagnosis of vulvar/vaginal atrophy

D. Huse, L. Palmer, G. Lenhart, 2014, Current medical research and opinion.

Pharmacokinetics and Tolerability of a Novel 17β-Estradiol and Progesterone Intravaginal Ring in Sheep.

Bridget A. Martell, J. Vidal, G. Constantine, 2019, Journal of pharmaceutical sciences.

Pharmacokinetics and tolerability of a novel progesterone intravaginal ring in sheep

Bridget A. Martell, J. Vidal, G. Constantine, 2019, Drug Delivery and Translational Research.

A conceptual time window‐based model for the early stratification of trauma patients

Y. Vodovotz, E. Elster, T. Billiar, 2019, Journal of internal medicine.

Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3‐Year, Randomized, Placebo‐, and Active‐Controlled Clinical Trial

Claus Christiansen, Harry K Genant, C. Christiansen, 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effects of Bazedoxifene on BMD and Bone Turnover in Postmenopausal Women: 2‐Yr Results of a Randomized, Double‐Blind, Placebo‐, and Active‐Controlled Study

C. Christiansen, P. Delmas, H. C. Hoeck, 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Clinical experience with trimegestone as a new progestin in HRT

G. Constantine, J. Pickar, G. Grubb, 2003, Steroids.

Healthy Postmenopausal Women Receiving HRT Are Not at Risk for Early Coronary Events: Results from 2 Large Clinical Trials

E. Trott, G. Constantine, J. Pickar, 2002 .

A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.

G. Constantine, R. Kagan, D. Archer, 2018, Obstetrics and gynecology.

Prescribing of FDA-approved and compounded hormone therapy differs by specialty

G. Constantine, D. Archer, S. Mirkin, 2016, Menopause.

Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety.

G. Constantine, D. Archer, J. Pickar, 2009, American journal of obstetrics and gynecology.

Temporal trends and drug exposures in pulmonary hypertension: an American experience.

L. Abenhaim, B. Strom, S. Rich, 2006, American heart journal.

A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause.

G. Constantine, D. Archer, J. Pickar, 2009, American journal of obstetrics and gynecology.

TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE Trial.

L. Derogatis, J. Simon, G. Constantine, 2016, The journal of sexual medicine.

Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone

D. Revicki, G. Constantine, S. Mirkin, 2019, Menopause.

Consistency of Effect with a Low-Dose, Estradiol Vaginal Capsule (TX-004HR): Evaluating Improvement in Vaginal Physiology and Moderate-to-Severe Dyspareunia in Subgroups of Postmenopausal Women

G. Constantine, D. Archer, C. Bouchard, 2017, Journal of women's health.

TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol

H. Kushner, J. Simon, G. Constantine, 2017, Menopause.

Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.

R. Lindsay, J. Gallagher, G. Constantine, 2009, Fertility and sterility.

Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms

D. Revicki, G. Constantine, R. Kagan, 2019, Menopause.

Ospemifene's effect on vasomotor symptoms: a post hoc analysis of phase 2 and 3 clinical data

G. Constantine, D. Archer, Wei Jiang, 2016, Menopause.

Behaviours and attitudes influencing treatment decisions for menopausal symptoms in five European countries

H. Currie, G. Constantine, S. Mirkin, 2016, Post reproductive health.

Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study

S. Silverman, D. Felsenberg, J. Adachi, 2011, Osteoporosis International.

Efficacy and Tolerability of Desvenlafaxine Succinate Treatment for Menopausal Vasomotor Symptoms: A Randomized Controlled Trial

G. Constantine, M. Gass, L. Speroff, 2008, Obstetrics and gynecology.

Increased Incidence of Endometrial Cancer Following the WHI: An Assessment of Risk Factors [18OP]

G. Constantine, S. Goldstein, G. Kessler, 2017 .

An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome.

E. Freeman, A. Rapkin, G. Constantine, 2011, Contraception.

Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women

A. Chines, G. Constantine, D. Archer, 2009, Menopause.

Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal japanese women with osteoporosis

A. Chines, T. Sugimoto, G. Constantine, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities.

T. Ryan, J. Jollis, J. Kisslo, 2000, Circulation.

In Reply.

H. Kushner, J. Simon, G. Constantine, 2017, Menopause.

O-206: Bazedoxifene combined with conjugated estrogens: A novel alternative to traditional hormone therapies

G. Constantine, J. Pickar, S. Ronkin, 2006 .

TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial

D. Revicki, J. Simon, G. Constantine, 2020, Menopause.

Improvement in sleep outcomes with a 17β-estradiol–progesterone oral capsule (TX-001HR) for postmenopausal women

G. Constantine, R. Kagan, S. Mirkin, 2018, Menopause.

Return to fertility after cessation of a continuous oral contraceptive.

K. Barnhart, G. Constantine, S. Mirkin, 2009, Fertility and sterility.